SLC16A1 and neoplasm: Similarly, several novel MCT1/4 inhibitors are under investigation, including AZD3965, which has demonstrated anti-tumor effects by inhibiting MCT1, disrupting lactate metabolism in tumors, and causing lactate accumulation within cancer cells.